Clinical Trial Update: Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With RR DLBCL, Including Patients With MYC Alterations [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including MYC-altered cases, has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• CUDC-907 (fimepinostat)

Snippet

Sponsor: Curis, Inc. | Conditions: Relapsed and/or Refractory Diffuse Large B-cell Lymphoma Including With Myc Alterations | Phase 2 | Status: COMPLETED | Results posted: 2022-04-27